Home
About
Overview
Sharing Data
ORCID
Help
History (1)
A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.
A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecol Oncol. 2007 May; 105(2):508-16.
View in:
PubMed
subject areas
Aged
Aged
Aged, 80 and over
Aged, 80 and over
Angiogenesis Inhibitors
Angiogenesis Inhibitors
Antigens, CD
Antigens, CD
Biomarkers, Tumor
Biomarkers, Tumor
Disease-Free Survival
Disease-Free Survival
Endometrial Neoplasms
Endometrial Neoplasms
Endothelial Protein C Receptor
Endothelial Protein C Receptor
Enzyme-Linked Immunosorbent Assay
Enzyme-Linked Immunosorbent Assay
Female
Female
Fibroblast Growth Factor 2
Fibroblast Growth Factor 2
Humans
Humans
Middle Aged
Middle Aged
Neovascularization, Pathologic
Neovascularization, Pathologic
Receptors, Cell Surface
Receptors, Cell Surface
Thalidomide
Thalidomide
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor A
authors with profiles
Doris M Benbrook